Most Read Articles
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
6 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
15 Mar 2019
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
4 days ago
Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.

Gene score predicts prostate cancer risk

18 Jan 2018

A polygenic hazard score appears to accurately estimate genetic risk and predict age at onset of aggressive prostate cancer, a recent study shows.

Using single nucleotide polymorphisms of 31,747 males, the researchers developed a polygenic hazard score to assess individual prostate cancer genetic risk and applied it to a cohort of 6,411 males. The main outcome was the predictive accuracy for age of onset of aggressive malignancy in the validation cohort.

According to a Cox proportional hazards model, the polygenic hazard score showed significant predictive ability for the age of onset of aggressive prostate cancer (z=11.2; p<10-16), any prostate cancer (z=15.4; p<10-16) and very aggressive prostate cancer (z=6.8; p<10-11).

Those in the >98th percentile of polygenic hazard scores were identified as high-risk patients and showed significantly higher risks of any prostate cancer (hazard ratio [HR], 2.5; 95 percent CI, 2.2–2.8), aggressive disease (HR, 3.0; 2.2–4.0) and early age of onset (HR, 2.9; 2.4–3.4).

A model developed using only aggressive prostate cancer cases also showed significant predictive value but did not outperform the original model (z=9.4; p<10-16; HR, 2.6; 2.1–3.1).

In a subsequent Cox test performed on patients with known family history statuses, there was no correlation between age of onset of aggressive disease and family history (z=0.9; p=0.37; HR, 1.1; 0.9–1.4).

Inclusion of family history in the model did not improve the predictive value over the original polygenic hazard score for any prostate cancer (p=0.14) or aggressive prostate cancer (p=0.59).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 4 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
6 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
15 Mar 2019
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).
4 days ago
Patients undergoing urgent/emergent percutaneous coronary intervention (PCI) and unable to take oral medications are good candidates for treatment with cangrelor, according to a new meta-analysis.